Ren Yifan, Chen Yuzhang, Zheng Wenbin, Kong Wen, Liao Yunfei, Zhang Jiaoyue, Wang Meng, Zeng Tianshu
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Diabetes and Metabolic Disease Clinical Research Center of Hubei Province, Wuhan, China.
Diabetes Obes Metab. 2025 Jul;27(7):3607-3626. doi: 10.1111/dom.16366. Epub 2025 Apr 15.
To investigate whether the antidiabetic agent glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can exert anti-inflammatory effects while lowering blood glucose, we performed a meta-analysis and systematic review.
We searched 4 online databases (Medline, Embase, Cochrane Library and the Web of Science) for randomised controlled trials (RCTs) that examined changes after GLP-1RAs intervention in commonly accepted biomarkers of inflammation: C-reactive protein (CRP), tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), leptin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), monocyte chemotactic protein-1(MCP-1) and advanced glycation end products (AGEs).
This meta-analysis included 52 eligible RCTs (n = 4734) with a median follow-up of 24 weeks, a mean age of 54.13 years, 44.46% females, body mass index (BMI) 29.80 kg/m, glycated haemoglobin (HbA1c) 8.28% and diabetes duration 7.27 years. GLP-1 RAs treatment, compared to placebo or conventional diabetes therapies (including oral medicine and insulin), resulted in significant reductions in CRP, TNF-α, IL-6, IL-1β and leptin (standard mean difference [SMD] -0.63 [-1.03, -0.23]; SMD -0.92 [-1.57, -0.27]; SMD -0.76 [-1.32, -0.20], SMD -3.89 [-6.56, -1.22], SMD -0.67 [-1.09, -0.26], respectively), as well as significant increases in adiponectin (SMD 0.69 [0.19, 1.19]).
Our meta-analysis demonstrates that GLP-1 RAs exert significant anti-inflammatory effects in patients with T2DM. Our findings provide important insights that may guide the therapeutic application of GLP-1 RAs and inform the development of related therapies.
为了研究抗糖尿病药物胰高血糖素样肽-1受体激动剂（GLP-1 RAs）在降低血糖的同时是否能发挥抗炎作用，我们进行了一项荟萃分析和系统评价。
我们在4个在线数据库（Medline、Embase、Cochrane图书馆和科学网）中检索随机对照试验（RCT），这些试验研究了GLP-1 RAs干预后常见的炎症生物标志物的变化：C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-1β（IL-1β）、瘦素、脂联素、纤溶酶原激活物抑制剂-1（PAI-1）、单核细胞趋化蛋白-1（MCP-1）和晚期糖基化终产物（AGEs）。
这项荟萃分析纳入了52项符合条件的RCT（n = 4734），中位随访时间为24周，平均年龄为54.13岁，女性占44.46%，体重指数（BMI）为29.80kg/m，糖化血红蛋白（HbA1c）为8.28%，糖尿病病程为7.27年。与安慰剂或传统糖尿病治疗（包括口服药物和胰岛素）相比，GLP-1 RAs治疗使CRP、TNF-α、IL-6、IL-1β和瘦素显著降低（标准化均数差[SMD]分别为-0.63[-1.03，-0.23]；SMD -0.92[-1.57，-0.27]；SMD -0.76[-1.32，-0.20]，SMD -3.89[-6.56，-1.22]，SMD -0.67[-1.09，-0.26]），同时脂联素显著升高（SMD 0.69[0.19，1.19]）。
我们的荟萃分析表明，GLP-1 RAs在2型糖尿病患者中发挥显著的抗炎作用。我们的研究结果提供了重要的见解，可能指导GLP-1 RAs的治疗应用，并为相关治疗的开发提供信息。
